ArticleThe Journal of cell biology1997
Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism.
Article in The Journal of cell biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 115 citations in OpenAlex.
- Multiple Roles for Neuregulins and Their v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog Receptors in Neurodegenerative Disease Pathogenesis and Therapy.The American journal of pathology · 2025Review
- The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.Pharmacological reviews · 2022Review
- Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.The American journal of pathology · 2019Review
- ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.Cell communication and signaling : CCS · 2019Article
- Post-translational modification of the interferon-gamma receptor alters its stability and signaling.The Biochemical journal · 2017Article
- A structural perspective on the regulation of the epidermal growth factor receptor.Annual review of biochemistry · 2015Review
- Deletion of ErbB4 accelerates polycystic kidney disease progression in cpk mice.Kidney international · 2014Article
- An iron-regulated and glycosylation-dependent proteasomal degradation pathway for the plasma membrane metal transporter ZIP14.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation.Biochimica et biophysica acta · 2014Article
- Sequential proteolytic processing of an interferon-alpha receptor subunit by TNF-alpha converting enzyme and presenilins.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012Article
- WWP1: a versatile ubiquitin E3 ligase in signaling and diseases.Cellular and molecular life sciences : CMLS · 2012Review
- Control of interneuron dendritic growth through NRG1/erbB4-mediated kalirin-7 disinhibition.Molecular psychiatry · 2012Article
- Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3.Molecular biology of the cell · 2011Article
- A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- ErbB4 regulates the timely progression of late fetal lung development.Biochimica et biophysica acta · 2010Article
- MUC1 is a substrate for gamma-secretase.Journal of cellular biochemistry · 2009Article
- Article
- Review
- Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.Cancer science · 2009Article
- The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.Molecular and cellular biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The heregulin receptor tyrosine kinase ErbB-4 is constitutively cleaved, in the presence or absence of ligand, by an exofacial proteolytic activity producing a membrane-anchored cytoplasmic domain fragment of 80 kD. Based on selective sensitivity to inhibitors, the proteolytic activity is identified as that of a metalloprotease. The 80-kD product is tyrosine phosphorylated and retains tyrosine kinase activity. Importantly, the levels of this fragment are controlled by proteasome function. When proteasome activity is inhibited for 6 h, the kinase-active 80-kD ErbB-4 fragment accumulates to a level equivalent to 60% of the initial amount of native ErbB-4 (approximately 10(6) receptors per cell). Hence, proteasome activity is essential to prevent the accumulation of a significant level of ligand-independent, active ErbB-4 tyrosine kinase generated by metalloprotease activity. Proteasome activity, however, does not act on the native ErbB-4 receptor before the metalloprotease-mediated cleavage, as no ErbB-4 fragments accumulate when metalloprotease activity is blocked. Although no ubiquitination of the native ErbB-4 is detected, the 80-kD fragment is polyubiquitinated. The data, therefore, describe a unique pathway for the processing of growth factor receptors, which involves the sequential function of an exofacial metalloprotease and the cytoplasmic proteasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.